Prizes & Non-dilutive Grants won
$5 million
Winners of Elon Musk’s XPRIZE 2021, Shell New Energy Challenge 2023, Horizon Europe 2024
Carbon-negative biomanufacturing: The new way of making everything
About
Plants absorb CO2 and synthesise complex molecules. We can now get a microbe to do this 50-80 times faster, cheaper and with more control.
Cells are the most powerful molecular architects. Since 1978, we’ve been programming cells to synthesise compounds for us that are too difficult for chemical processes to make.
We can now programme a special kind of cell, to build whatever we ask it to produce. But this cell is unique - it is powered exclusively by the world’s most abundant energy source (light). And feeds exclusively on the world’s most abundant pollutant (CO2).
METRICS
$40/T CO2
Price of carbon capture (2026)
70+
GMO strains engineered
4
Biological products
2
Projects delivered
$3.7m
Pre-orders
Supply chain resilience
Synthesise drug molecules from anywhere. No steel bioreactors. No sterile facilities. No costly media or ingredients.
Breakthrough low costs and emission avoidance generated
$40bn worth of high value biomolecules can be synthesised in a carbon-negative process. The best part? It costs less to do it this way.
Step 4
High-Value Output
Our process yields pharmaceutical compounds, biomaterials, and enzymes, representing a $40+ billion market. Generated up to 30% cheaper, this transforms carbon sequestration into a profitable byproduct.
Powered by the world’s most efficient photosynthetic organism.
Step 1
The Rolls-Royce engine
A patented genetically engineered microbe that boasts the world’s fastest CO2 fixation rate. Doubling every 2 hours.
Step 2
Reprogramming biology
Patented cloning methods, CRISPR-Cas12a, cre-Lox marker-free methods, a proprietary library of genetic parts and two years of in-house development. Now able to turn new strains from idea to launch in nine weeks.
Step 3
Plug-and-play integration
Our Photo-Bioreactor (PBR) systems integrate seamlessly. Inputs are simplified: CO2, water, NPK salts, and light. This ensures broad applicability and efficient deployment for industrial partners.
How we work
Our Technology Process
What’s the limit?
Industrial Enzymes
Pharmaceuticals
Chemicals
Bio-plastics
Bio-graphite
Battery Graphite
Bio-fuels
Materials Science
Our technology achieves unparalleled precision in converting atmospheric carbon directly into commercial-grade compounds.
Insulin (RHI)
Case Study
We are the first company globally to successfully synthesise human insulin from a photosynthetic microbe.
By leveraging the CO2-fixing power of our engineered organisms, we can produce this vital compound not only efficiently but also at a significantly lower cost than current conventional methods.
This innovative process enables a carbon-negative pathway for pharmaceutical production. Our groundbreaking technology is currently awaiting FDA approval, poised to revolutionise the availability and economics of critical medicines.
News and Insights
Modular • Profitable • Scalable • Low-Energy • Biological Precision •
Pipeline (cGMP)
Insulin (RHI)
Interferon-alpha
2x more products (TBC - Q1 2026)
The Science
Synthetic Biology: Precision Carbon Engineering
Leveraging our patented organism, we accelerate CO2 fixation. Targeted biomanufacturing yields recombinant insulin, pharmaceutical precursors, and battery anodes.
Now offering fixed supply agreements with 30%
cheaper than market price guarantee.
New website launching soon
